| إسرائيل | تركيا | إسبانيا | |
| العلاج المناعي مع Keytruda (Pembolizumab) | من $9,800 | من $3,300 | من $15,000 |
| العلاج الكيميائي لسرطان الثدي | من $22,500 | من $1,200 | من $3,500 |
| العلاج الكيميائي | من $2,400 | من $2,430 | من $2,500 |
| العلاج البيولوجي | - | من $5,500 | من $15,000 |
| العلاج الإشعاعي لسرطان القولون والمستقيم | - | من $7,000 | من $10,000 |
رئيس قسم أمراض الدم في مركز سوراسكي الطبي، يقود فريق المستشفى لرعاية مرضى سرطان الدم.
أجرى مئات عمليات زرع الخلايا الجذعية - يتخصص الدكتور رام في الحالات المعقدة التي تتطلب هذا الإجراء المتقدم في مركز سوراسكي الطبي.
أجرت الدكتورة رونيت إل حاسيد أكثر من 300 عملية زراعة نخاع عظم ودم حبل سري للأطفال، وتترأس القسم في مستشفى دانة دويك للأطفال في سوراسكي.
البروفيسور آموس تورين، MD، PhD، MHA، اختصاصي أمراض دم وأورام الأطفال وخبير زرع نخاع العظم. شغل منصب مدير أمراض دم وأورام الأطفال وزرع نخاع العظم في مركز شيبا الطبي.
حاصل على البورد في طب الأطفال، وأمراض دم وأورام الأطفال، وزرع نخاع العظم. يحمل دكتوراه في علم الوراثة البشرية. ترأس شعبة أمراض الدم في جامعة تل أبيب لولايتين. وهو عضو في ASH وCOG وESPHI وEBMT وCIBMTR، ويعمل أيضاً في لجنة دم الحبل السري بوزارة الصحة.
قاد أحد أكثر برامج أورام الأطفال وزرع نخاع العظم تقدماً في إسرائيل. عالج البرنامج الأطفال والشباب اليافعين. يشمل تركيزه ابيضاض الدم والأورام اللمفاوية، ونقص المناعة، والسرطانات النادرة. يتخصص في زرع نخاع العظم والعلاج بالخلايا التائية CAR T.
تشمل أبحاثه الترجمية خلايا CAR T، والخلايا القاتلة المحفزة بالسيتوكينات، وأورام الدماغ لدى الأطفال، والعلاجات الموجهة. تعاون مع St. Anna وNIH وSt. Jude. تتضمن منشوراته دراسات عن الوقاية في زرع الخلايا الجذعية لدى الأطفال (SCT) ومقاومة مثبطات PARP.
Israel reports exceptional Hodgkin lymphoma success rates, including a 100% one-year survival for patients using innovative chemo-biologic protocols. Clinics maintain a 90% average oncology success rate. Specialized centers achieve a 95% complete response rate using advanced chemotherapy and targeted biological therapy combinations.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center and Sourasky prioritize rapid adaptation based on diagnostic data. Experts like Dr. Abraham Avigdor use PET-CT scans after just two chemotherapy cycles to measure response. If the disease persists, they immediately switch to salvage therapies or clinical trials. This proactive approach explains why Israeli centers report higher remission rates than the global average.
Patient Consensus: Patients note that fertility preservation is a routine part of the process and usually covered. Many emphasize how the clean, well-run environment at clinics like Sourasky makes their treatment journey easier.
Israel offers advanced medical innovations like home-grown CAR-T cell therapy and TIL immunotherapies for hematologic cancers. Facilities like Sheba Medical Center and Sourasky Medical Center provide targeted drug treatments including Keytruda. Precise PET/CT-based prognostics help doctors tailor protocols for Hodgkin lymphoma and other complex conditions.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center maintain a 90% success rate by integrating research directly into clinical practice. Dr. Fredi Aviv has over 30 years of experience specifically in oncohematology clinical trials at this facility. Patients benefit from doctors who personally develop the protocols they administer.
Patient Consensus: Patients note it is important to choose JCI-accredited hospitals that offer all-inclusive support for smooth communication. Many highlight that local CAR-T options provide accessible alternatives to expensive international commercial drugs.
Israel is a global leader in Hodgkin lymphoma care. Major centers like Sheba Medical Center and Sourasky Medical Center offer advanced treatments. These include CAR T-cell therapy and bone marrow transplants. Facilities maintain Joint Commission International accreditation and high success rates.
Bookimed Expert Insight: While Sheba is famous for Newsweek rankings, Sourasky serves 1,800,000 patients yearly with 2,200 doctors. This high volume allows specialists like Dr. Fredi Aviv to focus only on blood cancers. Choosing these high-capacity centers often provides faster access to multidisciplinary teams.
Patient Consensus: Patients note that major centers like Sheba provide faster access to PET scans and immunotherapy than many Western hospitals. They emphasize the importance of English-speaking coordinators who help navigate the system without bureaucracy.
Standard Hodgkin lymphoma treatment in Israel typically lasts between 3 and 12 months. This duration includes 6 cycles of chemo for early stages. Cases involving CAR-T cell therapy or bone marrow transplants require 30 days of inpatient monitoring. All treatment plans involve regular PET-CT scans for progress tracking.
Bookimed Expert Insight: While chemotherapy cycles are predictable, advanced immunotherapy like CAR-T cell therapy offered at Sheba Medical Center follows a faster timeline but requires precise logistical coordination. Patients should account for a 2-week cell manufacturing period before the actual infusion. Data shows that clinics like Sourasky achieve a 90% success rate by strictly adhering to these treatment intervals without delays.
Patient Consensus: Patients note that low blood counts or minor infections can easily extend the timeline by 1 to 3 months. Many emphasize the importance of starting fertility preservation before the first cycle begins to avoid missing the window for future family planning.
Israeli medical centers provide structured support for international Hodgkin's lymphoma patients. Services include medical coordination, Jolnt Commission International (JCI) accredited safety protocols, and visa assistance. Facilities like Sheba Medical Center or Sourasky Medical Center offer dedicated international departments to manage logistics, including airport transfers and language interpretation.
Bookimed Expert Insight: Israeli hospitals often bundle extensive diagnostics into treatment packages to ensure accuracy. For instance, Sheba Medical Center includes PET/CT scans and specialist consultations within their bone marrow transplant programs. This approach eliminates the need for patients to arrange separate appointments, saving significant time during urgent treatment phases.
Patient Consensus: Patients note it's important to have a coordinator who speaks your language fluently. They often mention that having transportation pre-arranged by the clinic significantly reduces stress when arriving in a new country.